Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Benzalkonium chloride + benzocaine is an over-the-counter topical combination medication used primarily to treat cold sores and fever blisters. It combines two active ingredients with complementary actions: - Benzalkonium chloride is a quaternary ammonium compound that acts as an antiseptic, helping to prevent infection at the site of application. - Benzocaine is an ester local anesthetic that provides temporary pain relief by blocking nerve signal transmission through inhibition of sodium channels in neuronal membranes. This combination works by numbing the affected area (benzocaine) and reducing the risk of secondary infection (benzalkonium chloride). It is available in various topical forms, including creams and single-dose solutions. The product is marketed under brand names such as Orajel Single Dose and Orajel Cold Sore[3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on benzalkonium chloride + benzocaine.